AstraZeneca Results Presentation Deck
Net debt and capital allocation priorities
FY 2021 dividend increased to $2.87 (intended annualised dividend increase of $0.10)
$bn
12.1
Net debt
end 2020
Net debt: $24,322m; EBITDA¹: $7,586m
(6.0) 1.1
CFO
Net debt
Capex
0.5
Deal payments
and receipts²
3.9
Dividend
0.4
Other
12.1
Net debt end
2021 ex
aqusition
12.3
Acquisition
related³
Net debt/EBITDA: 3.2x
Net debt/EBITDA adjusted for
Alexion inventory fair value uplift4: 2.5x
24.3
Net debt
end 2021
●
●
●
●
Capital allocation priorities
Strong investment grade credit rating
Reinvestment in the business
Value-enhancing business development
Progressive dividend policy5
1. Earnings before interest, tax, depreciation and amortisation 2. Comprises purchase and disposal of intangible assets, payment of contingent consideration from business combinations, purchase and disposal of non-current asset
investments, movement in profit participation liability and disposal of investments in associates and joint ventures 3. Comprises for Alexion acquisition: Upfront payment of ($13,349m), payments upon vesting of employee share awards
($211m) and movement in net debt related to acquisitions +$1,307m. AstraZeneca credit ratings: Moody's: short-term rating P-2, long-term rating A3, outlook negative. S&P Global Ratings: short-term rating A-2, long-term rating A-,
15 CreditWatch neutral. 4. EBITDA adding back the impact of $2,198m (FY 2020: $nil) unwind of inventory fair value uplift recognised on acquisition of Alexion 5. Progressive dividend policy defined as either stable or increasing dividend per
share in US dollar terms.
&View entire presentation